NQMC Update Service: May 23, 2016 ► American Academy of Neurology

NQMC Update Service: May 23, 2016

American Academy of Neurology

• Amyotrophic lateral sclerosis (ALS): percentage of patients diagnosed with ALS and dysphagia, weight loss, or impaired nutrition who were offered at least once annually dietary or enteral nutrition support via percutaneous endoscopic gastrostomy or radiographic inserted gastrostomy.

• Amyotrophic lateral sclerosis (ALS): percentage of patients diagnosed with ALS for whom a multidisciplinary care plan was developed, if not done previously, and the plan was updated at least once annually.

• Amyotrophic lateral sclerosis (ALS): percentage of patients diagnosed with ALS who are dysarthric who were offered a referral at least once annually to a speech language pathologist for an augmentative/alternative communication evaluation.

• Amyotrophic lateral sclerosis (ALS): percentage of patients diagnosed with ALS who are screened at least once annually for cognitive impairment and behavioral impairment.

• Amyotrophic lateral sclerosis (ALS): percentage of patients diagnosed with ALS who were offered at least once annually assistance in planning for end of life issues.

• Amyotrophic lateral sclerosis (ALS): percentage of patients diagnosed with ALS who were screened at least every 3 months for dysphagia, weight loss or impaired nutrition and the result(s) of the screening(s) was documented in the medical record.

• Amyotrophic lateral sclerosis (ALS): percentage of patients diagnosed with ALS with whom the clinician discussed at least once annually treatment options for noninvasive respiratory support (e.g., noninvasive ventilation [NIV], assisted cough).

• Amyotrophic lateral sclerosis (ALS): percentage of patients with a diagnosis of ALS who were queried about symptoms of respiratory insufficiency and referred for pulmonary function testing, maximum inspiratory pressure, sniff nasal pressure, or peak cough expiratory flow at least every three months.

• Amyotrophic lateral sclerosis (ALS): percentage of patients with a diagnosis of ALS with whom the clinician discussed disease modifying pharmacotherapy (riluzole) to slow ALS disease progression at least once annually.

• Amyotrophic lateral sclerosis (ALS): percentage of visits for patients with a diagnosis of ALS with patient queried about falls within the past 12 months.

• Amyotrophic lateral sclerosis (ALS): percentage of visits for patients with a diagnosis of ALS with patients offered treatment for pseudobulbar affect, sialorrhea, and ALS related symptoms.